The MIC and MBC of Sch 29482 (SCH), MK 0787, ceftriaxone and moxalactam were compared with each other and with cefaclor, cefamandole, cefoxitin, ticarcillin, gentamicin, and trimethoprim/sulphamethoxazole using a microdilution technique. SCH was more active than MK 0787 against Proteus mirabilis, Proteus vulgaris and Providencia spp. but less active against Streptococcus faecalis, Enterohacter cloacae, Citrobacter freundii and Acinetobacter spp. Pseudomonas aeruginosa was very sensitive to MK 0787 (MIC 90 =2 mg/l) but resistant to SCH (MIC 10 =mg/l). Ro 13–9904 was more active than either SCH or MK 0787 against Ent. cloacae, Serratia marcescens, Providencia spp. and Pr. mirahilis but activity varied against several other Gram-negative species, especially Ps. aeruginosa . Ceftriaxone was less active than either SCH or MK 0787 against the staphylococci. Ceftriaxone was generally more active than moxalactam against Gram-positive bacteria but was equally or less active against members of the Bacteroides fragilis group (MIC 90 =mg/l). Ceftriaxone was less active than SCH, MK 0787 and moxalactam against these strains. Most MBC values were within one doubling dilution of the MIC. This was true for both SCH and MK 0787 against Sir.faecalis. We conclude that SCH, MK 0787, ceftriaxone and moxalactam are highly active, broad-spectrum antimicrobials in vitro which have a remarkably wide range of coverage.
No takes yet. Share an insight, caveat, or question.
Pierson et al. (1982) studied this question.